Results 151 to 160 of about 24,853 (244)
Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study. [PDF]
Kiladjian JJ +15 more
europepmc +1 more source
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley +1 more source
Disseminated Tuberculosis Mimicking Metastatic Cancer During Ruxolitinib Therapy for Polycythemia Vera: A Case Report and Literature Review. [PDF]
Ono Y +4 more
europepmc +1 more source
The aging of the human body is a complex process driven by multiple contributing factors. Based on their underlying mechanisms, current anti‐aging interventions can be classified into six primary categories. This paper summarizes the most promising anti‐aging strategies within each class. ABSTRACT The global prevalence of aging and age‐related diseases
Feifei Li +4 more
wiley +1 more source
Ruxolitinib combined with azithromycin for scrub typhus-associated hemophagocytic lymphohistiocytosis in a child: a case report and narrative literature review. [PDF]
Dong X +7 more
europepmc +1 more source
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli +5 more
wiley +1 more source
Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review. [PDF]
Al-Asa'd Y +4 more
europepmc +1 more source
We aimed to establish a simple method for GII.17 human norovirus (HuNoV) replication and serial passaging using wild‐type J2 human intestinal enteroids (HIEs). Treatment with ruxolitinib and TAK‐779, which target interferon and chemokine signaling, respectively, enhances viral replication and enables serial passaging of GII.17. ABSTRACT Human norovirus
Eri Hiraishi +4 more
wiley +1 more source
Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results. [PDF]
Breccia M +4 more
europepmc +1 more source
ABSTRACT Background To synthesize the most current and relevant evidence regarding pruritus management in patients with atopic dermatitis (AD), and to identify implications for nursing assessment, education, monitoring, and follow‐up. Method An extensive literature search was conducted across multiple databases, including the Cochrane Library, Embase ...
Yuzhen Shen +3 more
wiley +1 more source

